Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Modalis Therapeutics Corporation ( (JP:4883) ) is now available.
Modalis Therapeutics Corporation announced a non-operating expense due to a foreign exchange loss of 23 million yen for the nine months ending September 30, 2025. This loss resulted from the revaluation of foreign currency-denominated assets and liabilities, reflecting the impact of exchange rate fluctuations on the company’s financials.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, focusing on the biotechnology industry. It specializes in developing innovative therapeutic solutions and is known for its work in gene therapy and related fields.
Average Trading Volume: 1,373,390
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.89B
See more data about 4883 stock on TipRanks’ Stock Analysis page.